Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Laterality and Neurochemical Findings in Parkinson's Disease

Laterality and Neurochemical Findings in Parkinson's Disease Abstract To the Editor. —In their recent article, Direnfeld and co-workers1 suggested a possible relationship between the side of greater involvement and the cerebrospinal fluid (CSF) neurochemical findings in Parkinson's disease (PD). Principally, the authors stressed that PD patients affected on the right side of the body (PDR) show significantly lower homovanillic acid (HVA) levels in the CSF than the PD patients affected on the left side (PDL). This finding was interpreted as evidence of functional/structural asymmetries of dopaminergic pathways in the central nervous system (CNS). However, in our studies on CNS degenerative diseases, which included the evaluation of CSF monoamine metabolite levels, we were not able to reproduce the results of the quoted authors. Subjects and Methods. —Forty subjects were selected for study and divided into four groups: healthy controls (15 subjects), PDR (five subjects), PDL (five subjects), and dementia of Alzheimer's type (DAT) (15 subjects). All were volunteers and gave their References 1. Direnfeld LK, Albert ML, Volicer L, et al: Parkinson's Disease: The possible relationship of laterality to dementia and neurochemical findings . Arch Neurol 1984;41:935-941.Crossref 2. Langlais PJ, McEntee WJ, Bird ED: A rapid, liquid chromatographic measurement of 3-methoxyphenylglycol and other monoamine metabolites in human cerebrospinal fluid . Clin Chem 1980;26:787-788. 3. Rinne UK, Sonninen V: Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease . Eur Neurol 1974;12:340-350.Crossref 4. Pletscher A, Bartholini G, Tissot R: Metabolic fate of L-dopa in cerebrospinal fluid and blood plasma of humans . Brain Res 1967;4:106-109.Crossref 5. Ogasahara S, Nishikawa Y, Takahashi M, et al: Dopamine metabolism in central nervous system after discontinuation of L-dopa therapy in patients with Parkinson's disease . J Neurol Sci 1984;66:151-163.Crossref 6. Gottfries CG, Gottfries I, Roos BE: Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia, and parkinsonism . J Neurochem 1969;16:1341-1345.Crossref 7. Palmer AM, Sims NR, Bowen DM, et al: Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia . J Neurol Neurosurg Psychiatry 1984;47:481-484.Crossref 8. Pinessi L, Rainero I, Bianco C, et al: CSF and plasma catecholamine levels in dementia of Alzheimer type, in Burrows GD, Norman TR (eds): Clinical and Pharmacological Studies in Psychiatric Disorders. London, J Libbey, in press. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Laterality and Neurochemical Findings in Parkinson's Disease

Laterality and Neurochemical Findings in Parkinson's Disease

Abstract

Abstract To the Editor. —In their recent article, Direnfeld and co-workers1 suggested a possible relationship between the side of greater involvement and the cerebrospinal fluid (CSF) neurochemical findings in Parkinson's disease (PD). Principally, the authors stressed that PD patients affected on the right side of the body (PDR) show significantly lower homovanillic acid (HVA) levels in the CSF than the PD patients affected on the left side (PDL). This finding was interpreted as...
Loading next page...
 
/lp/american-medical-association/laterality-and-neurochemical-findings-in-parkinson-s-disease-4Y4FrMuFWH
Publisher
American Medical Association
Copyright
Copyright © 1986 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1986.00520030003001
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. —In their recent article, Direnfeld and co-workers1 suggested a possible relationship between the side of greater involvement and the cerebrospinal fluid (CSF) neurochemical findings in Parkinson's disease (PD). Principally, the authors stressed that PD patients affected on the right side of the body (PDR) show significantly lower homovanillic acid (HVA) levels in the CSF than the PD patients affected on the left side (PDL). This finding was interpreted as evidence of functional/structural asymmetries of dopaminergic pathways in the central nervous system (CNS). However, in our studies on CNS degenerative diseases, which included the evaluation of CSF monoamine metabolite levels, we were not able to reproduce the results of the quoted authors. Subjects and Methods. —Forty subjects were selected for study and divided into four groups: healthy controls (15 subjects), PDR (five subjects), PDL (five subjects), and dementia of Alzheimer's type (DAT) (15 subjects). All were volunteers and gave their References 1. Direnfeld LK, Albert ML, Volicer L, et al: Parkinson's Disease: The possible relationship of laterality to dementia and neurochemical findings . Arch Neurol 1984;41:935-941.Crossref 2. Langlais PJ, McEntee WJ, Bird ED: A rapid, liquid chromatographic measurement of 3-methoxyphenylglycol and other monoamine metabolites in human cerebrospinal fluid . Clin Chem 1980;26:787-788. 3. Rinne UK, Sonninen V: Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease . Eur Neurol 1974;12:340-350.Crossref 4. Pletscher A, Bartholini G, Tissot R: Metabolic fate of L-dopa in cerebrospinal fluid and blood plasma of humans . Brain Res 1967;4:106-109.Crossref 5. Ogasahara S, Nishikawa Y, Takahashi M, et al: Dopamine metabolism in central nervous system after discontinuation of L-dopa therapy in patients with Parkinson's disease . J Neurol Sci 1984;66:151-163.Crossref 6. Gottfries CG, Gottfries I, Roos BE: Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia, and parkinsonism . J Neurochem 1969;16:1341-1345.Crossref 7. Palmer AM, Sims NR, Bowen DM, et al: Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia . J Neurol Neurosurg Psychiatry 1984;47:481-484.Crossref 8. Pinessi L, Rainero I, Bianco C, et al: CSF and plasma catecholamine levels in dementia of Alzheimer type, in Burrows GD, Norman TR (eds): Clinical and Pharmacological Studies in Psychiatric Disorders. London, J Libbey, in press.

Journal

Archives of NeurologyAmerican Medical Association

Published: Mar 1, 1986

References